Dubious diagnosis: The war on ‘prediabetes’ could be a boon for pharma—but is it good medicine?Charles Piller, Science, Mar. 7, 2019
ADA and some of its physician advisers who have discussed drug treatments for prediabetes receive extensive financial support from pharmaceutical companies. The organization and its advisers say the payments have not affected their recommendations.